M

Middle East Pharmaceutical Industries Company SJSC
SAU:4016

Watchlist Manager
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Watchlist
Price: 121.2 SAR 1.68% Market Closed
Market Cap: 2.4B SAR

Intrinsic Value

The intrinsic value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 72.51 SAR. Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 40%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
72.51 SAR
Overvaluation 40%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation History
Middle East Pharmaceutical Industries Company SJSC

Middle East Pharmaceutical Industries Company SJSC
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for Middle East Pharmaceutical Industries Company SJSC cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Middle East Pharmaceutical Industries Company SJSC
SAU:4016
SA
Pharmaceuticals
Market Cap
2.4B SAR
IPO
Feb 27, 2024
SA
Pharmaceuticals
Market Cap
2.4B SAR
IPO
Feb 27, 2024
Price
ď·Ľfalse
EPS
ď·Ľfalse
Middle East Pharmaceutical Industries Company SJSC
Company Overview
Loading...
Contacts
Loading...
How do you feel about Middle East Pharmaceutical Industries Company SJSC?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Middle East Pharmaceutical Industries Company SJSC
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Middle East Pharmaceutical Industries Company SJSC

Balance Sheet Decomposition
Middle East Pharmaceutical Industries Company SJSC

Current Assets 355.4m
Cash & Short-Term Investments 22.6m
Receivables 226.7m
Other Current Assets 106m
Non-Current Assets 171.4m
PP&E 120.8m
Intangibles 50.6m
Other Non-Current Assets -100
Efficiency

Free Cash Flow Analysis
Middle East Pharmaceutical Industries Company SJSC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Middle East Pharmaceutical Industries Company SJSC

Revenue
394m SAR
Cost of Revenue
-150.6m SAR
Gross Profit
243.4m SAR
Operating Expenses
-152.3m SAR
Operating Income
91m SAR
Other Expenses
-11.2m SAR
Net Income
79.8m SAR
Fundamental Scores

Profitability Score
Profitability Due Diligence

Middle East Pharmaceutical Industries Company SJSC's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Year Average ROE
Positive 3-Year Average ROIC
Positive Free Cash Flow
65/100
Profitability
Score

Middle East Pharmaceutical Industries Company SJSC's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Middle East Pharmaceutical Industries Company SJSC's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
85/100
Solvency
Score

Middle East Pharmaceutical Industries Company SJSC's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Middle East Pharmaceutical Industries Company SJSC

Wall Street analysts forecast Middle East Pharmaceutical Industries Company SJSC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Middle East Pharmaceutical Industries Company SJSC is 133.62 SAR with a low forecast of 132.31 SAR and a high forecast of 137.55 SAR.

Lowest
Price Target
132.31 SAR
9% Upside
Average
Price Target
133.62 SAR
10% Upside
Highest
Price Target
137.55 SAR
13% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Middle East Pharmaceutical Industries Company SJSC
does not pay dividends
Shareholder Yield

Current shareholder yield for Middle East Pharmaceutical Industries Company SJSC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one Middle East Pharmaceutical Industries Company SJSC stock?

The intrinsic value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 72.51 SAR.

Is Middle East Pharmaceutical Industries Company SJSC stock undervalued or overvalued?

Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 40%.

Back to Top